Processing

Please wait...

Settings

Settings

Goto Application

1. CN108367016 - A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION

Office
China
Application Number 201680068558.0
Application Date 22.11.2016
Publication Number 108367016
Publication Date 03.08.2018
Publication Kind A
IPC
A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
CPC
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants CAN-FITE BIOPHARMA LTD.
坎-菲特生物药物有限公司
Inventors FISHMAN PNINA
P·菲什曼
COHEN SHIRA
希拉·柯亨
Agents 北京安信方达知识产权代理有限公司 11262
北京安信方达知识产权代理有限公司 11262
Priority Data 242723 23.11.2015 IL
Title
(EN) A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION
(ZH) 用于治疗异位脂肪堆积的A3腺苷受体配体
Abstract
(EN)
The disclosure concerns A3AR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Also provided by the disclosure is the use of A3AR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, a method of treating a condition associates with fat accumulation making use of the ligand and kits comprising pharmaceutical compositions comprisingthe ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. In one embodiment, the disclosure provides the use of an A3AR agonist, such as 2-Chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (C1-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).

(ZH)
本公开内容涉及用于减少异位脂肪堆积、特别是脂肪肝中的异位脂肪堆积的A3AR配体。本公开内容还提供了A3AR配体用于制备用于减少这样的脂肪堆积的药物组合物的用途、利用该配体治疗与脂肪堆积相关的状况的方法、以及试剂盒,试剂盒包括含有该配体的药物组合物和使用药物组合物来治疗与异位脂肪堆积相关的状况的使用说明。在一个实施方案中,本公开内容提供A3AR激动剂例如2‑氯‑N6‑(3‑碘苄基)‑腺苷‑5'‑N‑甲基脲酰胺(Cl‑IB‑MECA,CF102)用于治疗脂肪肝、尤其是非酒精性脂肪肝病(NAFLD)的用途。